최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0808828 (2015-07-24) |
등록번호 | US-9701728 (2017-07-11) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 6 인용 특허 : 445 |
Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 r
Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.
1. A method of treating inflammation in a subject, comprising: contacting a liquid volume comprising white blood cells with polyacrylamide beads, the white blood cells at a concentration at least equal to a concentration of white blood cells in whole blood;separating the polyacrylamide beads from th
1. A method of treating inflammation in a subject, comprising: contacting a liquid volume comprising white blood cells with polyacrylamide beads, the white blood cells at a concentration at least equal to a concentration of white blood cells in whole blood;separating the polyacrylamide beads from the liquid volume to obtain a composition comprising interleukin 1 receptor antagonist (IL-1ra); andadministering the composition to the subject. 2. The method of claim 1, wherein the liquid volume comprises whole blood, a white blood cell fraction, a buffy coat fraction, a white blood cell isolate, platelet-rich plasma, or a combination thereof. 3. The method of claim 1, wherein contacting comprises incubating the liquid volume with the polyacrylamide beads for a time from about 30 seconds to about 24 hours. 4. The method claim 1, wherein the concentration of IL-1ra is at least 10,000 pg/ml. 5. A method of treating inflammation in a subject, comprising activating a liquid volume comprising white blood cells using a porous material to generate a composition comprising at least 10,000 pg/ml interleukin-1 receptor antagonist (IL-1ra), wherein the liquid volume has a concentration of white blood cells greater than a concentration of white blood cells in whole blood; and administering the composition to a site of inflammation in the subject. 6. The method of claim 5, wherein the porous material comprises absorptive beads. 7. The method of claim 5, wherein administering includes mixing the composition with fibrinogen, thrombin, calcium, an antibiotic, or a combination thereof, and applying the mixture to the site of inflammation. 8. The method of claim 5, wherein activating includes allowing the porous material to absorb a fluid of the liquid volume. 9. The method of claim 5, wherein the composition further comprises at least one protein selected from soluble tumor necrosis factor receptor-I, platelet-derived growth factor-AB, transforming growth factor β1, insulin-like growth factor-1, basic fibroblast growth factor, or vascular endothelial growth factor, wherein the selected protein is at a concentration greater than a concentration of the selected protein in whole blood. 10. A method of treating inflammation in a subject, comprising; providing a liquid volume comprising white blood cells at a concentration greater than a concentration of white blood cells in whole blood;concentrating the liquid volume to produce a composition having a concentration of interleukin-1 receptor antagonist (IL-1ra) of at least 10,000 pg/ml, including removing a portion of a fluid from the liquid volume; andadministering the composition to a site of inflammation in the subject. 11. The method of claim 10, wherein the white blood cells are isolated from a volume of whole blood, Of comprise a fraction of whole blood, a buffy coat fraction, platelet-rich plasma, or a combination thereof. 12. The method of claim 10, wherein concentrating includes mixing the liquid volume with an absorptive material. 13. The method of claim 10, wherein concentrating includes mixing the liquid volume with polyacrylamide beads. 14. The method of claim 10, wherein the liquid volume has a concentration of white blood cells of at least about 24,000/μL. 15. The method of claim 10, wherein the composition comprises at least about 20,000 pg/ml IL-1ra. 16. The method of claim 10, wherein the composition comprises at least about 30,000 pg/ml IL-1ra. 17. The method of claim 10, wherein concentrating includes removing at least about 50% of the fluid. 18. The method of claim 10, wherein the composition further comprises at least one protein selected from soluble tumor necrosis factor receptor-I, platelet-derived growth factor-AB, transforming growth factor β1, insulin-like growth factor-1, basic fibroblast growth factor, or vascular endothelial growth factor, wherein the selected protein has a concentration greater than a concentration of the selected protein in the whole blood or plasma of the subject. 19. The method of claim 10, wherein the composition comprises white blood cells, platelets, or both, of the subject. 20. The method of claim 10, further comprising administering to the site of inflammation an antibiotic, fibrinogen, thrombin, calcium from a source other than the composition, or a combination thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.